The ranks of our senior leadership are filled with highly knowledgeable, talented individuals. Each has many years of relevant experience and track records of success.

Scott Tarriff

Chief Executive Officer, Director

Mr. Tarriff is the founder and chief executive officer of Eagle Pharmaceuticals. Prior to joining Eagle, Mr. Tarriff held various executive positions at Par Pharmaceutical Companies, Inc. and Bristol-Myers Squibb, both publicly traded companies. At Par, he served as president and chief executive officer from September 2003 to September 2006, and was also a member of the board of directors from 2002 to September 2006.

Before that, Mr. Tarriff was a senior director of marketing at Bristol-Myers Squibb. He also previously served on the board of directors of Clinical Data, Inc., a publicly traded pharmaceutical company, from September 2009 to April 2011, when Clinical Data was acquired by Forest Laboratories, Inc.

He has a BS in marketing from Pennsylvania State University and an MBA from Rider College.

David Pernock

President and Chief Commercial Officer

Mr. Pernock is Eagle’s President and Chief Commercial Officer. He brings vast experience in the pharmaceutical and biotechnology space. Mr. Pernock served as a member of Eagle’s Board from April 2015 through December 2016.

Prior to Eagle, Mr. Pernock served as Chairman of the Board of Directors and Chief Executive Officer (2010 – 2017) of Fibrocell Science, Inc., a publicly-traded autologous cell and gene therapy company.

Mr. Pernock held various positions at GlaxoSmithKline, most notably serving as Senior Vice President of Pharmaceuticals, Vaccines (Biologics), Oncology, Acute Care, and HIV Divisions. He also served as President of Reliant Pharmaceuticals. Furthermore, Mr. Pernock served as a director of Martek Biosciences Corporation.

Mr. Pernock holds a B.S. in Business Administration from Arizona State University.

Pete A. Meyers

Chief Financial Officer

Pete A. Meyers is Eagle’s Chief Financial Officer and the Company’s principal financial officer and principal accounting officer.

Mr. Meyers has over two decades of experience in the health care industry. He most recently served as Chief Financial Officer of Motif BioSciences Inc., from May 2016 to January 2017. Prior to his role at Motif, he served as Chief Financial Officer and Treasurer of TetraLogic Pharmaceuticals Corporation from August 2013 to March 2016.

Mr. Meyers also spent 18 years as a health care investment banker, most recently as Co-Head of Global Health Care Investment Banking at Deutsche Bank Securities Inc. Mr. Meyers currently serves on the Board of Directors of Prima BioMed Ltd, where he chairs the Audit Committee.

Mr. Meyers holds an M.B.A in Finance from Columbia Business School and a B.S. in Finance from Boston College.

Adrian Hepner, MD, PhD

Executive Vice President and Chief Medical Officer

Dr. Hepner has over 25 years of experience in US and international clinical research and drug development. Included in his experience is the development and implementation of the clinical and regulatory strategy for a number of products from early stage development through successful New Drug Application (NDA) and EU regulatory filings.

After receiving his MD degree, Dr. Hepner completed visiting research physician experiences in the Department of Psychiatry at Harvard Medical School, the Department of Neurology at the National Institute of Mental Health, and a post-doctoral fellowship in neuropharmacology at the University of Ottawa. Additionally, he spent 17 years in neuropsychiatry private practice and participated in multiple clinical research studies.

Dr. Hepner’s pharmaceutical industry experience includes 15 years of progressively increasing drug development responsibilities. He had a critical leading role in the regulatory and clinical activities for FDA approval of the first product for pseudobulbar affect and successfully completing placebo-controlled studies in other indications. Most recently, Dr. Hepner held the role of vice president of clinical research and medical affairs at BioDelivery Sciences International (BDSI), where he led the regulatory review process for the first buccal film approved for the maintenance treatment of opioid dependence. In addition, he had a critical role in the commercial launch of the product.

Prior to BDSI, Dr. Hepner was senior medical director at UCB BioSciences, Inc., where he was responsible for global development projects in the central nervous system therapeutic area. He was also vice president of clinical research at Avanir Pharmaceuticals and led global clinical research projects in Latin America for Teva Pharmaceuticals.

Steven L. Krill, PhD

Executive Vice President/Chief Scientific Officer

Dr. Krill has served as Eagle Pharmaceuticals’ chief scientific officer since February 2013. Before that, he held the position of vice president of pharmaceutical development from October 2011 to February 2013. Prior to joining Eagle Pharmaceuticals, Dr. Krill served as the vice president of scientific affairs at Teva Parenteral Medicines. A few years prior, at Boehringer Ingelheim, Dr. Krill was vice president, pharmaceutical research and development (December 2005 to March 2009) and director of pharmaceutics and investigational supplies (May 2002 to December 2005). He has also held various management positions at Lipocine Inc., Novartis Pharmaceuticals, and Abbott Laboratories.

Dr. Krill is an author of over 30 publications and inventor of multiple patents in the area of drug delivery.

He holds a BS in pharmacy and an MS in pharmaceutical sciences from the University of Cincinnati and a PhD in Pharmaceutics from the University of Utah.

John LaRocca

Executive Vice President and General Counsel

Mr. LaRocca is an executive vice president and general counsel for Eagle Pharmaceuticals, and serves as the company’s chief compliance officer. He joined the company after a 15-year career with Actavis, serving in various functions within the legal department. Most recently he served as deputy general counsel, Americas. Mr. LaRocca was primarily responsible for managing the legal services supporting the branded and generic pharmaceutical businesses of Actavis in Canada, the United States, and Latin America.

Prior to going in-house, Mr. LaRocca was a practicing attorney in New York City for 11 years, specializing in mergers and acquisitions, securities compliance, and commercial litigation.

Mr. LaRocca has a JD from the Columbia School of Law and a BA from Columbia College.

Daniel O’Connor

Executive Vice President, Biologics and Corporate Development

Daniel J. O’Connor is the Executive Vice President of Biologics and Corporate Development for Eagle Pharmaceuticals. He joined the company in 2007 and served as finance director from 2011 to May 2013. Additionally, he served as interim chief financial officer in 2013.

Prior to joining Eagle, Mr. O’Connor held a variety of management positions, including senior analyst roles at Ethicon, a Johnson & Johnson Company subsidiary. He was also a lead finance liaison with Ethicon’s joint venture with Omrix Biopharmaceuticals. Mr. O’Connor held several finance positions at Ranbaxy Pharmaceuticals Inc., a wholly-owned subsidiary of Ranbaxy Inc. that markets generic products in the United States.

Mr. O’Connor has a B.S. in business administration from West Virginia University and an M.B.A. from Rutgers University.

Meet the Board of Directors.